Immunodeficiency; COVID-19 recurrent; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNODEFICIENCY (Immunodeficiency) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) solution for injection for an unknown indication and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 15-Aug-2021, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 07-Sep-2021, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) dosage was changed to 1 dosage form. On 04-May-2022, received third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Solution for injection in pre-filled pen. On an unknown date, the patient experienced IMMUNODEFICIENCY (Immunodeficiency) (seriousness criterion medically significant) and COVID-19 (COVID-19 recurrent). At the time of the report, IMMUNODEFICIENCY (Immunodeficiency) outcome was unknown and COVID-19 (COVID-19 recurrent) was resolving.            The concomitant medication was not reported by reporter. On unknown dates, the patient experienced covid twice and lower in immune system.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  Primary reporter did not have the lot number information, because the information was not available in the patient's file. The treatment medication was not reported by reporter.  Company comment- This spontaneous case concerns a female patient of unknown age with no relevant medical history, who experienced unexpected, serious (medically significant) event of Immunodeficiency and unexpected, non-serious AESI Covid-19 (reported as COVID-19 recurrent) which occurred at an unknown time with regards to vaccination with a fourth dose of mRNA-1273. The first three doses of COVID-19 vaccination were tozinameran, thus an interchange of vaccine products was also noted in the case. No further information was provided. The outcome of the event Covid-19 was reported as resolving. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a female patient of unknown age with no relevant medical history, who experienced unexpected, serious (medically significant) event of Immunodeficiency and unexpected, non-serious AESI Covid-19 (reported as COVID-19 recurrent) which occurred at an unknown time with regards to vaccination with a fourth dose of mRNA-1273. The first three doses of COVID-19 vaccination were tozinameran, thus an interchange of vaccine products was also noted in the case. No further information was provided. The outcome of the event Covid-19 was reported as resolving. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.